Matches in SemOpenAlex for { <https://semopenalex.org/work/W2729184498> ?p ?o ?g. }
- W2729184498 endingPage "61730" @default.
- W2729184498 startingPage "61719" @default.
- W2729184498 abstract "// Yan Qiao 1, 2, * , Shanshan Lu 1, * , Zhihui Xu 1, * , Xiaodong Li 1 , Kai Zhang 1, 4 ,Yan Liu 1 , Li Zhao 1 , Rongjuan Chen 1 , Lanlan Si 1 , Shumei Lin 4 , Dongping Xu 1, 2 and Jin Li 1, 3 1 Research Center for Clinical and Translational Medicine/Institute of Infectious Diseases, Beijing 302 Hospital, Beijing 100039, China 2 Clinical Medical School, Guilin Medical University, Guilin 541004, China 3 Medical Department, Beijing 302 Hospital, Beijing 100039, China 4 Department of Infectious Disease, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China * These authors have contributed equally to this work Correspondence to: Dongping Xu, email: xudongping302@sina.com Jin Li, email: lijin302@hotmail.com Keywords: hepatitis B virus, mutation, additional N-glycosylation, HBsAg/anti-HBs coexistence, hepatocellular carcinoma Received: December 22, 2016 Accepted: May 08, 2017 Published: June 27, 2017 ABSTRACT The study aimed to determine the association of additional N-glycosylation mutations in the major hydrophilic region (MHR) of hepatitis B virus (HBV) S gene with hepatocellular carcinoma (HCC) occurrence in HBsAg/anti-HBs coexistent patients. A total of 288 HBsAg/anti-HBs coexistent patients and 490 single HBsAg-positive patients were enrolled, including 193 with HCC, 433 with chronic hepatitis B (CHB), and 152 with acute-on-chronic liver failure (ACLF). The HBV S genes were amplified from serum and sequenced. The frequency of additional N-glycosylation mutations was significantly higher in HCC patients (12.37%) than in CHB patients (4.39%) and ACLF patients (2.63%). The frequency escalated by an order of single HBsAg-positive non-HCC (1.61%), single HBsAg-positive HCC (5.98%), HBsAg/anti-HBs coexistent non-HCC (8.01%), and HBsAg/anti-HBs coexistent HCC (22.36%). Twelve kinds of mutations/mutation patterns were detected, five of which have not been reported. Multivariate analysis showed that age > 40 years [ OR , 3.005; 95% CI, 1.177−7.674; P = 0.021], alpha-fetoprotein > 10 ng/mL [ OR , 4.718; 95% CI, 2.406−9.251; P <0.001], cirrhosis [ OR , 6.844; 95% CI, 2.773−16.891, P < 0.001], Hepatitis B e antigen negativity [ OR , 2.218; 95% CI, 4.335, P = 0.020], and additional N-glycosylation mutation [ OR , 2.831; 95% CI, 1.157−6.929; P = 0.023] were independent risk factors for HCC in HBsAg/anti-HBs coexistent patients. Dynamical analysis showed that the additional N-glycosylation mutations existed 1-4 years prior to HCC occurrence in eight of 18 patients observed. In conclusion, the dditional N-glycosylation mutations together with HBsAg/anti-HBs coexistence might serve as a predictive indicator for HCC occurrence in chronic HBV-infected patients." @default.
- W2729184498 created "2017-07-14" @default.
- W2729184498 creator A5003850660 @default.
- W2729184498 creator A5005522080 @default.
- W2729184498 creator A5008232261 @default.
- W2729184498 creator A5021293751 @default.
- W2729184498 creator A5029849405 @default.
- W2729184498 creator A5030801733 @default.
- W2729184498 creator A5035125189 @default.
- W2729184498 creator A5035645403 @default.
- W2729184498 creator A5065490078 @default.
- W2729184498 creator A5068350345 @default.
- W2729184498 creator A5071807699 @default.
- W2729184498 creator A5082357190 @default.
- W2729184498 date "2017-06-27" @default.
- W2729184498 modified "2023-09-27" @default.
- W2729184498 title "Additional N-glycosylation mutation in the major hydrophilic region of hepatitis B virus S gene is a risk indicator for hepatocellular carcinoma occurrence in patients with coexistence of HBsAg/anti-HBs" @default.
- W2729184498 cites W1091583100 @default.
- W2729184498 cites W1492134529 @default.
- W2729184498 cites W1626434939 @default.
- W2729184498 cites W1743808860 @default.
- W2729184498 cites W1788437999 @default.
- W2729184498 cites W1966468571 @default.
- W2729184498 cites W1985059554 @default.
- W2729184498 cites W1991624448 @default.
- W2729184498 cites W2012333875 @default.
- W2729184498 cites W2017572742 @default.
- W2729184498 cites W2018699646 @default.
- W2729184498 cites W2025283567 @default.
- W2729184498 cites W2036112973 @default.
- W2729184498 cites W2064081948 @default.
- W2729184498 cites W2079316096 @default.
- W2729184498 cites W2082120216 @default.
- W2729184498 cites W2086037121 @default.
- W2729184498 cites W2089145440 @default.
- W2729184498 cites W2105956766 @default.
- W2729184498 cites W2122635379 @default.
- W2729184498 cites W2122656069 @default.
- W2729184498 cites W2125690358 @default.
- W2729184498 cites W2155751613 @default.
- W2729184498 cites W2163102792 @default.
- W2729184498 cites W2405546459 @default.
- W2729184498 cites W2470787297 @default.
- W2729184498 cites W2475481560 @default.
- W2729184498 cites W4253457069 @default.
- W2729184498 doi "https://doi.org/10.18632/oncotarget.18682" @default.
- W2729184498 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5617459" @default.
- W2729184498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28977899" @default.
- W2729184498 hasPublicationYear "2017" @default.
- W2729184498 type Work @default.
- W2729184498 sameAs 2729184498 @default.
- W2729184498 citedByCount "15" @default.
- W2729184498 countsByYear W27291844982018 @default.
- W2729184498 countsByYear W27291844982020 @default.
- W2729184498 countsByYear W27291844982021 @default.
- W2729184498 countsByYear W27291844982022 @default.
- W2729184498 countsByYear W27291844982023 @default.
- W2729184498 crossrefType "journal-article" @default.
- W2729184498 hasAuthorship W2729184498A5003850660 @default.
- W2729184498 hasAuthorship W2729184498A5005522080 @default.
- W2729184498 hasAuthorship W2729184498A5008232261 @default.
- W2729184498 hasAuthorship W2729184498A5021293751 @default.
- W2729184498 hasAuthorship W2729184498A5029849405 @default.
- W2729184498 hasAuthorship W2729184498A5030801733 @default.
- W2729184498 hasAuthorship W2729184498A5035125189 @default.
- W2729184498 hasAuthorship W2729184498A5035645403 @default.
- W2729184498 hasAuthorship W2729184498A5065490078 @default.
- W2729184498 hasAuthorship W2729184498A5068350345 @default.
- W2729184498 hasAuthorship W2729184498A5071807699 @default.
- W2729184498 hasAuthorship W2729184498A5082357190 @default.
- W2729184498 hasBestOaLocation W27291844981 @default.
- W2729184498 hasConcept C104317684 @default.
- W2729184498 hasConcept C126322002 @default.
- W2729184498 hasConcept C159047783 @default.
- W2729184498 hasConcept C2522874641 @default.
- W2729184498 hasConcept C2777382497 @default.
- W2729184498 hasConcept C2777410769 @default.
- W2729184498 hasConcept C2778019345 @default.
- W2729184498 hasConcept C2780593183 @default.
- W2729184498 hasConcept C2994225774 @default.
- W2729184498 hasConcept C501734568 @default.
- W2729184498 hasConcept C54355233 @default.
- W2729184498 hasConcept C71924100 @default.
- W2729184498 hasConcept C86803240 @default.
- W2729184498 hasConcept C90924648 @default.
- W2729184498 hasConceptScore W2729184498C104317684 @default.
- W2729184498 hasConceptScore W2729184498C126322002 @default.
- W2729184498 hasConceptScore W2729184498C159047783 @default.
- W2729184498 hasConceptScore W2729184498C2522874641 @default.
- W2729184498 hasConceptScore W2729184498C2777382497 @default.
- W2729184498 hasConceptScore W2729184498C2777410769 @default.
- W2729184498 hasConceptScore W2729184498C2778019345 @default.
- W2729184498 hasConceptScore W2729184498C2780593183 @default.
- W2729184498 hasConceptScore W2729184498C2994225774 @default.
- W2729184498 hasConceptScore W2729184498C501734568 @default.
- W2729184498 hasConceptScore W2729184498C54355233 @default.
- W2729184498 hasConceptScore W2729184498C71924100 @default.
- W2729184498 hasConceptScore W2729184498C86803240 @default.